The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications documents the industry’s increasing commitment to developing personalized medicines in oncology.  This special report, published in conjunction with the Personalized Medicine Coalition (PMC), is the first comprehensive quantitative examination of a cancer biomarker database.

Whereas previous analyses of the pharmaceutical pipeline, including the one PMC commissioned five years ago, relied on impressionistic survey data, this more definitive study analyzes the Aggregate Analysis of Clinical Trials, a cloud-based platform on which all clinical trials are registered.

Related Insights